Life Sciences Compensation Remains Strong For Senior Leaders

The state-of-pay in the life sciences industry continues to be strong – very strong.

According to the latest State-Of-Pay Reports from Marsh McLennan Agency (MMA), compensation for CEOs, Chief Financial Officers, General Counsels and board directors is at an all-time high.

To download MMA’s compensation analysis of each job title, please click here.

“The life sciences industry remains a standout in terms of valuation creation for shareholders and for society as a whole,” said Jeremy Anderson, Principal and Director of the Compensation Consulting Division for MMA. “MMA’s analyses show that executive leaders in life sciences are being rewarded for delivering breakthrough products and services and increasing the enterprise value of their companies.”

MMA’s analysis is based on regulatory filings from publicly traded companies on the West Coast. The companies include biotechnology, pharma, biomedical and life systems and those involved research, development, technology transfer and commercialization.

CEO Comp Tops $2.5 Million

For CEOs, MMA found that median total direct compensation for CEOs was $2.5 million. Of that, almost 80% was bonus and long-term incentive pay – at risk compensation based on the company’s performance.

The median base salary was $550,000 and long-term incentive comp was $1.5 million. “Surprisingly, fewer organizations are using stock options only,” Anderson said. “A significant number of companies are now mixing options and full value shares.”

To see all four compensation reports, click here.

MMA’s Compensation Consulting Practice provides unmatched expertise in executive compensation, board compensation, sales effectiveness, and broad-based rewards. For more information, contact Jeremy Anderson or visit us online: